Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1]. The trial investigated ...
Some results have been hidden because they may be inaccessible to you